In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma

A case series reporting on four adult patients with multiple myeloma. Patients had confirmed BCMA expression, had received at least two prior therapies, and had disease that was refractory or that had progressed on immunomodulators and proteasome inhibitors. The results of the case series indicate that ESO-T01 may eradicate extramedullary disease, but larger randomized studies with longer follow-up are needed to confirm efficacy and safety.